[1]
|
Brugieres, L., Branchereau, S. and Laithier, V. (2012) Paediatric malignant liver tumours. Bulletin du Cancer, 99, 219-228.
|
[2]
|
Salhab, M. and Canelo, R. (2011) An overview of evidence-based management of hepatocellular carcinoma: A meta-analysis. Journal of Cancer Research and Therapeutics, 7, 463-475. doi:10.4103/0973-1482.92023
|
[3]
|
Michielsen, P.P., Francque, S.M. and van Dongen, J.L. (2005) Viral hepatitis and hepatocellular carcinoma. World Journal of Surgical Oncology, 3, 27.
doi:10.1186/1477-7819-3-27
|
[4]
|
Parkin, D.M., et al. (2005) Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians, 55, 74-108.
doi:10.3322/canjclin.55.2.74
|
[5]
|
Farrell, G.C., Yuen, M.F., Amarapurkar, D.N., Chutaputti, A., Fan, J.G., Hou, J.L., Han, K.H., Kao, J.H., Lim, S.G., Mohamed, R., Sollano, J. and Ueno, Y. (2010) Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements. Journal of Gastroenterology and Hepatology, 25, 657-663.
|
[6]
|
Altekruse, S.F., McGlynn, K.A. and Reichman, M.E. (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. Journal of Clinical Oncology, 27, 1485-1491.
doi:10.1200/JCO.2008.20.7753
|
[7]
|
Capocaccia, R., et al. (2007) Hepatocellular carcinoma: Trends of incidence and survival in Europe and the United States at the end of the 20th century. American Journal of Gastroenterology, 102, 1661-1670.
|
[8]
|
Baatarkhuu, O., et al. (2011) Current situation of hepatocellular carcinoma in Mongolia. Oncology, 81, 148-151.
doi:10.1159/000333278
|
[9]
|
Oyunsuren, T., et al. (2006) Hepatocellular carcinoma and its early detection by AFP testing in Mongolia. Asian Pacific Journal of Cancer Prevention, 7, 460-462.
|
[10]
|
Yuen, M.F., Hou, J.L. and Chutaputti, A. (2009) Hepatocellular carcinoma in the Asia pacific region. Journal of Gastroenterology and Hepatology, 24, 346-353.
doi:10.1111/j.1440-1746.2009.05784.x
|
[11]
|
Marrero, C.R. and Marrero, J.A. (2007) Viral hepatitis and hepatocellular carcinoma. Archives of Medical Research, 38, 612-620. doi:10.1016/j.arcmed.2006.09.004
|
[12]
|
Nguyen, V.T., Law, M.G. and Dore, G.J. (2009) Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. Journal of Viral Hepatitis, 16, 453-463. doi:10.1111/j.1365-2893.2009.01117.x
|
[13]
|
Tarantino, G. (2007) Utility of sonography in diagnosing hepatocellular carcinoma. American Journal of Roentgenology, 188, 494-495.
|
[14]
|
Soresi, M., et al. (2003) Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Research, 23, 1747-1753.
|
[15]
|
Giardina, M.G., et al. (1998) Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: A prospective study of patients with cirrhosis. Cancer, 83, 2468-2474. doi:10.1002/(SICI)1097-0142(19981215)83:12<2468::AID-CNCR9>3.0.CO;2-Y
|
[16]
|
Ansari, N.A. and Derias, N.W. (1997) Fine needle aspiration cytology. Journal of Clinical Pathology, 50, 541-543.
doi:10.1136/jcp.50.7.541
|
[17]
|
Wee, A. (2005) Fine needle aspiration biopsy of the liver: Algorithmic approach and current issues in the diagnosis of hepatocellular carcinoma. Cytojournal, 2, 7.
doi:10.1186/1742-6413-2-7
|
[18]
|
Livni, N., et al. (1995) p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer, 75, 2420-2426.
doi:10.1002/1097-0142(19950515)75:10<2420::AID-CNCR2820751006>3.0.CO;2-6
|
[19]
|
Oiwa, H., et al. (1995) Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer, 75, 1454-1459.
doi:10.1002/1097-0142(19950315)75:6+<1454::AID-CNCR2820751511>3.0.CO;2-G
|
[20]
|
Crocker, J. (1990) AgNORs and follicular lymphomas. Journal of Clinical Pathology, 43, 964-965.
doi:10.1136/jcp.43.11.964
|
[21]
|
Nayak, S.K., Panesar, P.S. and Kumar, H. (2011) Nongenotoxic p53-activators and their significance as antitumor therapy of future. Current Medicinal Chemistry, 18, 1038-1049. doi:10.2174/092986711794940833
|
[22]
|
Scheistroen, M., et al. (1999) p53 protein expression in squamous cell carcinoma of the vulva. Cancer, 85, 1133-1138.
doi:10.1002/(SICI)1097-0142(19990301)85:5<1133::AID-CNCR17>3.0.CO;2-T
|
[23]
|
Cheng, L., et al. (1999) p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer, 85, 1293-1299.
doi:10.1002/(SICI)1097-0142(19990315)85:6<1293::AID-CNCR11>3.0.CO;2-O
|
[24]
|
Chen, F., Wang, W. and El-Deiry, W.S. (2010) Current strategies to target p53 in cancer. Biochemical Pharmacology, 80, 724-730.
doi:10.1016/j.bcp.2010.04.031
|
[25]
|
Garcia, J.F., et al. (1997) p53 expression in CMV-infected cells: Association with the alternative expression of the p53 transactivated genes p21/WAF1 and MDM2. Histopathology, 30, 120-125.
doi:10.1046/j.1365-2559.1997.d01-577.x
|
[26]
|
Sivridis, E. and Sims, B. (1990) Nucleolar organiser regions: New prognostic variable in breast carcinomas. Journal of Clinical Pathology, 43, 390-392.
doi:10.1136/jcp.43.5.390
|
[27]
|
Smith, P.J., et al. (1988) The effect of a series of fixatives on the AgNOR technique. Journal of Pathology, 155, 109-112. doi:10.1002/path.1711550206
|
[28]
|
Beresford, M.J., Wilson, G.D. and Makris, A. (2006) Measuring proliferation in breast cancer: Practicalities and applications. Breast Cancer Research, 8, 216.
doi:10.1186/bcr1618
|
[29]
|
Karki, S., Jha, A. and Sayami, G. (2012) The role of argyrophilic nucleolar organizer region (AgNoR) study in cytological evalution of fluids, especially for detection of malignancy. Kathmandu University Medical Journal (KUMJ), 10, 44-47.
|
[30]
|
Siddiqui, M.S., et al. (1999) Assessment of nucleolar organizer regions (NORs) in proliferative conditions of the liver. Pathology Research and Practice, 195, 421-426.
doi:10.1016/S0344-0338(99)80016-8
|
[31]
|
WMA, (2010) World Medical Association Declaration of Helsinki: Ethical principles for medical research involveing human subjects. http://www.wma.net/e/policy/b3.htm.
|
[32]
|
Trere, D. (2000) AgNOR staining and quantification. Micron, 31, 127-131. doi:10.1016/S0968-4328(99)00069-4
|
[33]
|
Crocker, J. (1996) Molecular and biochemical aspects of interphase nucleolar organiser regions. Journal of Clinical Pathology, 49, M8-M11.
doi:10.1136/mp.49.1.M8
|
[34]
|
Chiu, K.Y., Loke, S.L. and Wong, K.K. (1989) Improved silver technique for showing nucleolar organiser regions in paraffin wax sections. Journal of Clinical Pathology, 42, 992-994. doi:10.1136/jcp.42.9.992
|
[35]
|
Chiaramonte, M., et al. (1999) Rate of incidence of heaptocellular carcinoma in patients with compensated viral cirrhosis. Cancer, 85, 2132-2137.
doi:10.1002/(SICI)1097-0142(19990515)85:10<2132::AID-CNCR6>3.0.CO;2-H
|
[36]
|
Roa, I., et al. (1997) p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology, 31, 226-230.
doi:10.1046/j.1365-2559.1997.2420850.x
|
[37]
|
Hogmo, A., et al. (1998) Nuclear DNA content and p53 overexpression in stage I squamous cell carcinoma of the tongue compared with advanced tongue carcinomas. Molecular Pathology, 51, 268-272. doi:10.1136/mp.51.5.268
|
[38]
|
Yaziji, H., et al. (1996) Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. American Journal of Surgical Pathology, 20, 1086-1090. doi:10.1097/00000478-199609000-00006
|
[39]
|
Ojanguren, I., et al. (1995) p53 immunoreactivity in heaptocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular carcinoma. Histopathology, 26, 63-68. doi:10.1111/j.1365-2559.1995.tb00622.x
|
[40]
|
Raedle, J., et al. (1995) Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Digestive Diseases and Sciences, 40, 2587-2594.
doi:10.1007/BF02220446
|
[41]
|
Ojanguren, I., et al. (1996) p53 immunoreaction in heaptocellular carcinoma and its relationship to etiologic factors. A fine needle aspiration study. Acta Cytologica, 40, 1148-1153. doi:10.1159/000333973
|
[42]
|
Wee, A., et al. (1994) Fine needle aspiration biopsy of hepatocellular carcinoma. Diagnostic dilemma at the ends of the spectrum. Acta Cytologica, 38, 347-354.
|
[43]
|
Darnton, S.J. and Jenner, K. (1998) Microwave irradiation lowers immunohistological detection thresholds for p53 protein in squamous epithelium from non-neoplastic oesophagus. The Journal of Pathology, 185, 334-335.
doi:10.1002/(SICI)1096-9896(199807)185:3<334::AID-PATH36>3.0.CO;2-0
|
[44]
|
Iakova, P., Timchenko, L. and Timchenko, N.A. (2011) Intracellular signaling and hepatocellular carcinoma. Seminars in Cancer Biology, 21, 28-34.
doi:10.1016/j.semcancer.2010.09.001
|
[45]
|
Guan, Y.S., et al. (2007) p53 gene in treatment of hepatic carcinoma: status quo. World Journal of Gastroenterology, 13, 985-992.
|
[46]
|
Hsia, C.C., et al. (2000) Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma. Oncology Reports, 7, 353-356.
|
[47]
|
Derenzini, M., et al. (1993) Is high AgNOR quantity in hepatocytes associated with increased risk of hepatocellular carcinoma in chronic liver disease? Journal of Clinical Pathology, 46, 727-729. doi:10.1136/jcp.46.8.727
|
[48]
|
Aubele, M., Auer, G. and Jutting, U. (1994) Prognostic value of AgNORs in breast cancer. Zentralblatt für Pathologie, 140, 55-60.
|
[49]
|
Crocker, J. and McGovern, J. (1988) Nucleolar organiser regions in normal, cirrhotic, and carcinomatous livers. Journal of Clinical Pathology, 41, 1044-1048.
doi:10.1136/jcp.41.10.1044
|
[50]
|
Dervan, P.A., et al. (1989) Breast carcinoma kinetics. Argyrophilic nucleolar organizer region counts correlate with Ki67 scores. American Journal of Clinical Pathology, 92, 401-407.
|
[51]
|
Raymond, W.A. and Leong, A.S. (1989) Nucleolar organizer regions relate to growth fractions in human breast carcinoma. Human Pathology, 20, 741-746.
doi:10.1016/0046-8177(89)90066-X
|
[52]
|
Ascoli, V., et al. (1990) Nucleolar organizer regions in the fine needle aspirates of lung tumours. Cytopathology, 1, 277-286. doi:10.1111/j.1365-2303.1990.tb00361.x
|
[53]
|
Allen, J.P. and Gallimore, A.P. (1992) Nucleolar organizer regions in benign and malignant glandular lesions of the cervix. The Journal of Pathology, 166, 153-156.
doi:10.1002/path.1711660211
|
[54]
|
Pich, A., Margaria, E. and Chiusa, L. (2002) Significance of the AgNOR in tumor pathology. Pathologica, 94, 2-9.
|
[55]
|
Yu, C.C., et al. (1992) A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours. The Journal of Pathology, 166, 147-152. doi:10.1002/path.1711660210
|
[56]
|
Shiro, T., et al. (1993) A correlation of argyrophilic nucleolar organizer regions with stages of hepatocellular carcinoma. Cancer, 71, 44-49.
doi:10.1002/1097-0142(19930101)71:1<44::AID-CNCR2820710108>3.0.CO;2-L
|